Clinical trial NCT00571493: VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
Official title: Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Non-hodgkin's Lymphoma
Mantle Cell Lymphoma
Keywords: non-hodgkin's lymphoma
mantle cell lymphoma
BEAM
Velcade
Lead sponsor: University of Nebraska
Sponsor class: OTHER
Collaborators: name: Millennium Pharmaceuticals, Inc.
First posted: 2007-12-12
Enrollment: 42
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase I/II trial designed to study the toxicity and Maximum Tolerated Dose (MTD) of bortezomib in combination with BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) and autologous hematopoietic stem cell transplantation (ASCT) and to obtain a preliminary estimate of the response rate to this combination.

Detailed description: Primary Objective:The primary objective of the study is to evaluate the toxicity and determine the maximum tolerated dose (MTD) of bortezomib when added to a standard BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) conditioning regimen followed by autologous hematopoietic stem cell transplantation (ASCT).

Secondary Objective: The secondary objective of the study is to obtain a preliminary estimate of the overall response rate (ORR), progression free survival (PFS), and overall survival (OS) with this regimen.

Enrolled subjects will receive bortezomib in combination with BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) and autologous hematopoietic stem cell transplantation (AHSCT). Phase I treatment will administer bortezomib in four dose cohorts,in addition to the BEAM and ASCT. Three patients will be accrued in each dose cohort with enrollment starting at dose cohort. These subjects will be evaluated to establish the maximum tolerated dose of bortezomib in combination with BEAM autologous peripheral blood stem cell transplantation. Once established, the maximum tolerated dose will be utilized in treating an additional 20 subjects.

Follow-Up: Data collected will be utilized to obtain a preliminary estimate of the overall response rate, progressions free survival and overall survival using this regimen.

Eligibility criteria: Inclusion Criteria:

* Persistent, relapsed or refractory indolent non-Hodgkin's lymphoma (Follicular grade I, II, or III), non-Hodgkin's lymphoma, composite lymphomas with ≥ 50% of tumor showing follicular histology, transformed follicular, lymphoplasmacytic, marginal zone lymphoma, small Lymphocytic Lymphoma (including T-cell subtypes), or mantle cell lymphoma that is relapsed, refractory, or in PR1 or CR1 (MCL only for CR1).
* Age \>19 years.
* Signed written informed consent.
* Expected survival duration of \> six months.
* Karnofsky Performance Status \> 70.
* Eligible patients must have: Liver functions \< 3x upper limits of normal (ULN) unless due to disease; ANC \> 500 cells/mm3 and Platelet Count \> 50 mm3.
* Patients \> age 60 or with clinical signs of heart disease must have ejection fraction ≥ 45% LVEF.
* Patients with clinical signs of pulmonary insufficiency must have DLCO to be measured at \> 50% of predicted value.
* Able to collect \> 1.2 X 106/kg CD34+ cell for transplantation.
* No serious disease or condition that, in the opinion of the investigator, would compromise the patient's ability to participate in the study.
* Female patients must not be pregnant or lactating.
* Male and female patients of reproductive potential must follow accepted birth control measures.

Exclusion Criteria:

* Patients who are HIV seropositive
* Serum creatinine \>2.5mg/dL or calculated creatinine clearance ≤ 50ml/min
* Total bilirubin \>3 times upper limits of normal (unless due to Gilberts disease or malignancy), ALT and AST \>4 times the upper limits of normal
* Active infection at the time of transplant
* Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
* Patient has hypersensitivity to bortezomib, boron or mannitol.
* Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) of Bortezomib
timeFrame: 14 months
Secondary outcomes:
measure: Preliminary Estimate of Overall Response Rate (ORR)
timeFrame: 100 day post autologous hematopoietic stem cell transplantation (ASCT), one year post ASCT
measure: Progression-free Survival (PFS), and Overall Survival (OS)
timeFrame: one year post autologous hematopoietic stem cell transplantation (ASCT) , 5 years post ASCT
Other outcomes:
Locations:
city: Omaha
country: United States
facility: University of Nebraska Medical Center
state: Nebraska
Study officials:
affiliation: University of Nebraska
name: Julie M Vose, MD
role: STUDY_CHAIR
References: